Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 5/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30768105 | 1.00 | CYP11B2 (0.41) | CYP11B2ACACBGPR119SCD5PIK3R1 | |
| SCHEMBL27035007 | 0.86 | CYP11B2 (0.41) | CYP11B2ACACBSCD5PIK3R1PIK3CA | |
| SCHEMBL30768119 | 0.86 | CYP11B2 (0.41) | CYP11B2ACACBSCD5PIK3R1PIK3CA | |
| SCHEMBL27034828 | 0.82 | CCNE1 (0.39) | CYP11B2GPR119 | |
| SCHEMBL31591029 | 0.79 | GPR119 (0.35) | ACACBGPR119PIK3R1PIK3CA | |
| SCHEMBL30327698 | 0.74 | CYP11B2 (0.46) | CYP11B2ACACBGPR119SCD5PIK3R1 | |
| SCHEMBL29575451 | 0.74 | GLP1R (0.36) | — | |
| SCHEMBL20203404 | 0.74 | GLP1R (0.36) | — | |
| SCHEMBL27034852 | 0.71 | CCNE1 (0.42) | CYP11B2ACACB | |
| SCHEMBL30329057 | 0.71 | CYP11B2 (0.47) | CYP11B2ACACBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. | 2024-02-01 | — | — | US | disclosed |
| WO-2024020419-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020419-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | CCNI, CDKN1A, CDK8 | CYP11B2 2189/4885ACACB 664/4885GPR119 2222/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | CYP11B2 325/4885ACACB 4438/4885GPR119 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.